University of California, San Francisco
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, University of California, San Francisco sits in the top decile of US sponsors by registered trial count (#10 of 15,742 sponsors by registered trial count).
University of California, San Francisco: 1,713 sponsored US clinical trials, 272 recruiting.
University of California, San Francisco sponsors 1,713 registered US clinical trials on ClinicalTrials.gov, 272 of them currently recruiting, and 1,130 completed. 196 of these trials are in Phase 3-4 (later-stage) and 359 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 18 trials.
Top-decile sponsor footprint
University of California, San Francisco ranks in the top decile of sponsors by registered trial count (#10 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
1,130 of 1,305 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (86.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
1,713 total, page 27 of 35
Chitinases and Transforming Growth Factor Beta (TGFB) in Human Asthma
NCT01073410
The Navigator Project
NCT02106702
Early Aggressive Pain Management is Associated With Improved Outcomes in Blunt Thoracic Trauma
NCT01327287
Anticoagulation Length of ThErapy and Risk of New Adverse evenTs In Venous thromboEmbolism Study
NCT03292666
Trial of Methyl B12 on Behavioral and Metabolic Measures in Children With Autism
NCT01039792
Effect of Maraviroc on Endothelial Function in HIV-Infected Patients
NCT00844519
Palliation of Thirst in ICU Patients
NCT01015755
A Pilot Clinical Trial of Varenicline as a Treatment for Alcohol Dependence
NCT01011907
Slow Paced-Respiration Intervention to Reduce Incontinence Trial (SPIRIT)
NCT01048424
Davunetide (AL-108) in Predicted Tauopathies - Pilot Study
NCT01056965
The Effects of a Mediterranean Diet in Pediatric Hyperlipidemia
NCT01308710
Neonatal Erythropoietin in Asphyxiated Term Newborns
NCT00719407
Effect of Nalbuphine and Naloxone on Experimentally Induced Skin Sensitivity
NCT00947284
Pilot Study of a Catheter-based Ultrasound Hyperthermia System
NCT00911079
Ketoconazole and Dexamethasone in Prostate Cancer
NCT01036594
Project RAP: Family-based HIV Prevention in the Juvenile Drug Court
NCT01403298
Microaspiration in Pulmonary Fibrosis
NCT01150591
Comparison of Low Yield Cigarettes in African Americans vs. Whites
NCT01058876
HIV Persistence and Viral Reservoirs
NCT01025427
Pilot Study on the Tolerability of Dietary Dried Plum
NCT01035372
Practicing Restorative Yoga or Stretching for the Metabolic Syndrome
NCT01024816
Optimizing Cognitive Remediation Outcomes in Schizophrenia
NCT02105779
Study of Gamma-Knife Radiosurgery Using Magnetic Resonance Imaging (MRI) Spectroscopy for Recurrent Glioma
NCT01011231
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma
NCT01008917
Feasibility of Using SPECT/CT Imaging to Map Lymphatic Drainage Patterns in Prostate Cancer Patients
NCT01008969
Dose-dependent Effects of Second-hand Smoke on Vascular Function
NCT01007760
Cardiovascular Risk Markers in Patients With Rheumatoid Arthritis: Effect of Rituximab Therapy
NCT00844714
Targeted, Dose-Escalation Busulfan-Etoposide as Prep Regimen
NCT01048827
Global and Regional Myocardial Strain and Power Output In Patients With Single Ventricles Using Novel MRI Techniques
NCT01107990
Laparoscopic Revision Gastric Bypass for Inadequate Initial Weight Loss
NCT01040377
The FLU-FOBT Program in Primary Care Settings Where Disparities Persist
NCT01211379
FLU-FIT Program at Kaiser Permanente Northern California
NCT01210235
Laparoscopic Revision of Vertical Banded Gastroplasty to Gastric Bypass
NCT01041131
Comparison of Hookah and Cigarette Smoking
NCT00992550
A Pilot Study of Acupoint Injection for Primary Dysmenorrhea
NCT00995917
A Study of Withdrawal of Immunosuppression and Donor Lymphocyte Infusions Following Allogeneic Transplant for Pediatric Hematologic Malignancies
NCT01036009
Laparoscopic Revision Gastric Bypass for Weight Recidivism
NCT01040572
Panobinostat and Epirubicin in Treating Patients With Metastatic Malignant Solid Tumors
NCT00878904
Long-term Cardiac Monitoring After Cryptogenic Stroke (CMACS)
NCT00932425
Radiosurgery or Open Surgery for Epilepsy Trial
NCT00860145
Atherosclerosis in Rheumatoid Arthritis
NCT00990730
Practicing Alternative Techniques to Heal From Depression: The PATH-D Study
NCT00871299
Lay Health Workers and Colorectal Cancer Screening Among Chinese Americans
NCT00947206
Cognitive Remediation of Schizophrenia in a Community Mental Health Setting
NCT01988714
Effect of Early Limited Formula Use on Breastfeeding Outcomes
NCT00952328
Randomized Controlled Clinical Trial of Weight Loss Programs in Obese Persons
NCT00960414
Peer Coaching for Low-Income Patients With Diabetes in Primary Care
NCT01040806
Adding Malabsorption for Failed Gastric Bypass
NCT01040481
Trial Embedded in an Electronic Personal Medical Health Records
NCT00972348
Comparing the Efficacy of Ultravate Ointment in Combination With Lac-Hydrin Lotion in the Treatment of Psoriasis
NCT00990561
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 193 |
| Phase 2 | 166 |
| Phase 3 | 44 |
| Phase 4 | 152 |
Therapeutic Areas
What is open in the University of California, San Francisco pipeline
272 recruiting of 1,713 indexed (16% open); 1,130 completed (66%).
Phase mix: 196 late (III/IV) vs 359 early (I/II) (early-phase heavy).
Top condition: Breast Cancer (18 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
University of California, San Francisco: open-pipeline peers nationwide
Peers matched on 1,713 registered trials and 16% open enrollment, not the therapeutic-area sidebar.
University of California, San Francisco sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1,713 trials (± recruiting share)
- Duke University · 1,725 trials · 11% recruiting
- Stanford University · 1,744 trials · 15% recruiting
- VA Office of Research and Development · 1,668 trials · 17% recruiting
- Pfizer · 1,845 trials · 6% recruiting
Sponsors near 16% open enrollment (± trial volume)
- University of Oregon · 16% recruiting · 63 trials
- Fox Chase Cancer Center · 16% recruiting · 183 trials
- Youngstown State University · 16% recruiting · 19 trials
- ECOG-ACRIN Cancer Research Group · 16% recruiting · 75 trials
Related
What to do with this University of California, San Francisco page
1,713 registered trials is a research-attention snapshot, not an endorsement of University of California, San Francisco or any single study.
- 272 of University of California, San Francisco's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Breast Cancer is the condition University of California, San Francisco studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Breast Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. University of California, San Francisco pipeline card: 1,713 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.